Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

Next Previous
Trial Profile

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary) ; Guselkumab
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms IXORA-R
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 21 Mar 2023 Results of post-hoc pooled analysis assessing NPF treatment targets in the overall population, and biologic-experienced and -naive subpopulations across IXORA-R, IXORA-S, integrated UNCOVER-2-3 presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results(n=54) comparing the early effects of IXE and GUS on psoriasis pathway genes in lesions between baseline and weeks 1, 2, and 4, presented at the American Academy of Dermatology annual Meeting 2023
    • 13 Mar 2022 Results assessing simultaneous skin and nail clearance in patients with psoriasis across five head-to-head trials (IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, and SPIRIT-H2H) comparing ixekizumab with other biologics, published in the Dermatology and Therapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top